Aligos Therapeutics Abstracts On Incremental Data From ALG-000184 In CHB Subjects And Late-Breaker Oral Presentation Of Data From Phase 2a HERALD Study Of ALG-055009 In MASH Subjects Accepted At Liver Meeting 2024
Portfolio Pulse from Benzinga Newsdesk
Aligos Therapeutics has announced that abstracts on incremental data from their ALG-000184 in chronic hepatitis B (CHB) subjects and a late-breaker oral presentation of data from the Phase 2a HERALD study of ALG-055009 in metabolic-associated steatohepatitis (MASH) subjects have been accepted at the Liver Meeting 2024.
October 15, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aligos Therapeutics' abstracts on ALG-000184 and ALG-055009 have been accepted for presentation at the Liver Meeting 2024, indicating progress in their clinical trials for CHB and MASH.
The acceptance of abstracts for presentation at a major conference like the Liver Meeting 2024 suggests positive progress in Aligos Therapeutics' clinical trials. This can boost investor confidence and potentially lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100